webinar Automating functional cell-based bioassays: assay reproducibility and performance for potency testing programmes 28 May 2021 | By Eurofins DiscoverX* and Tecan In this on-demand webinar, we discuss how Eurofins DiscoverX’s off-the-shelf, MOA-based functional, cellular assays address these challenges, enabling drug discovery programmes up to late-stage development and market release.
whitepaper Catalogue: Drug target reagents 20 April 2021 | By Sino Biological Inc. 5,000+ drug target reagents for antibody, small molecule drug discovery and development, including immune checkpoints, cytokines and kinases.
webinar Novel small molecule inhibitors of oncogenic SHP2 variants characterised by cellular target engagement 28 January 2021 | By Eurofins DiscoverX & Sanford Burnham Prebys Discovery In this on-demand webinar industry experts discuss how the InCELL Pulse technology provides a valuable tool for the discovery and characterisation of novel SHP2 inhibitors.
news Apilimod small molecule shows potent inhibition of SARS-CoV-2 in cells 7 August 2020 | By Victoria Rees (Drug Target Review) Researchers have found the small molecules Apilimod and Vacuolin-1 inhibited the PIKfyve kinase in cells, preventing infection from Zaire ebolavirus and SARS-CoV-2.
whitepaper Application note: A kinase inhibitor phenotypic screen using a multiplex T Cell activation assay 22 June 2020 | By IntelliCyt Corporation Modulating the TCR signaling pathway using biologics, small molecules or genetic engineering is highly relevant to many therapeutic areas including cancer immunotherapy, adoptive cell therapy, vaccine development and autoimmune disease.
news Binding site of drug compound and tumour suppressor protein revealed 21 April 2020 | By Victoria Rees (Drug Target Review) Using cyro-electron microscopy, researchers have imaged the binding site between a molecule and the tumour suppressor protein PP2A, enabling optimisation of the drug compound.
article Targeted protein degradation: the next wave of therapeutics 23 March 2020 | By Victoria Rees (Drug Target Review) Using the ubiquitin-proteasome system to fight inflammatory conditions could provide more treatment options for patients. Dr Jared Gollob from Kymera Therapeutics explains why targeted protein degradation is the way forward for autoinflammatory and autoimmune disease therapies.
news Researchers gain new insight into LRRK2 – a potential cause of Parkinson’s 20 February 2020 | By Mandy Parrett (Drug Target Review) Scientists in the US have applied a novel technique to finally unravel a particular kinase enzyme that is associated with familial Parkinson’s disease; providing a clearer potential therapeutic target.
news Research into CDK8 oncogene could improve design of future therapeutics 29 January 2020 | By Hannah Balfour (Drug Target Review) A study has shown that type II kinase inhibitors targeting CDK8 alone are ineffective because mutations leave them inactive, suggesting future therapies should target CDK8 in complex.
article Expert view: Promising methods in kinase screening 12 December 2019 | By BMG Labtech GmbH Kinase-mediated phosphorylation is a control point for nearly all activity within a cell, making kinases important in many diseases.
news Kinase identified as potential target for heart failure treatment 1 November 2019 | By Rachael Harper (Drug Target Review) A new study has shown that restoring the amount of the kinase, HIPK2, in a kinase-depleted mouse model rescued it from heart failure and identifies HIPK2 as a novel regulator of heart failure progression.
article SEL120: a promising CDK8 kinase inhibitor 28 October 2019 | By Victoria Rees (Drug Target Review) A novel CDK8 inhibitor has been developed by scientists at Ryvu Therapeutics. Dr Krzysztof Brzozka showcases this molecule and explains the R&D behind it.
news Inhibiting kinase improves arrhythmogenic cardiomyopathy symptoms 5 September 2019 | By Victoria Rees (Drug Target Review) A research team has found that blocking a particular kinase in a mouse model of arrhythmogenic cardiomyopathy led to improved survival rates.
news Blocking kinase could provide treatment for prostate cancer 29 August 2019 | By Victoria Rees (Drug Target Review) Researchers have found that inhibiting a kinase in mice leads to the death of prostate cancer cells, providing a potential therapeutic target.
